Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
JCAR-014 by Bristol-Myers Squibb for Mantle Cell Lymphoma: Likelihood of Approval
JCAR-014 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
JCAR-014 by Bristol-Myers Squibb for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
JCAR-014 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
JCAR-014 by Bristol-Myers Squibb for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
JCAR-014 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...
JCAR-014 by Bristol-Myers Squibb for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
JCAR-014 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
JCAR-014 by Bristol-Myers Squibb for Non-Hodgkin Lymphoma: Likelihood of Approval
JCAR-014 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase...